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Abstract
Genetically-modified mutants are now indispensable Plasmodium gene-function reagents, which are also being pursued as
genetically attenuated parasite vaccines. Currently, the generation of transgenic malaria-parasites requires the use of drug-
resistance markers. Here we present the development of an FRT/FLP-recombinase system that enables the generation of
transgenic parasites free of resistance genes. We demonstrate in the human malaria parasite, P. falciparum, the complete
and efficient removal of the introduced resistance gene. We targeted two neighbouring genes, p52 and p36, using a
construct that has a selectable marker cassette flanked by FRT-sequences. This permitted the subsequent removal of the
selectable marker cassette by transient transfection of a plasmid that expressed a 37uC thermostable and enhanced FLP-
recombinase. This method of removing heterologous DNA sequences from the genome opens up new possibilities in
Plasmodium research to sequentially target multiple genes and for using genetically-modified parasites as live, attenuated
malaria vaccines.
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Introduction
The genomes of several different Plasmodium species are either
completely sequenced, or near to completion. This includes those
of the most important human malaria parasites, P. falciparum and
P. vivax, as well as three closely related rodent species; P. chabaudi,
P. yoelii and P. berghei[1,2,3,4]. Comparative analyses of Plasmodium
genomes and genomes of other organisms have greatly improved
the identification and assignation of putative functions to
Plasmodium genes, and these analyses have revealed that about
50% of malaria parasites genes cannot be assigned a function by
homology and it is therefore likely that many of these genes
perform functions that are unique to Plasmodium. In the absence of
efficient forward genetic screens, reverse genetics, specifically
targeted gene deletion and phenotype analysis, is currently the
front line methodology to study Plasmodium specific gene function
[5]. Currently, the permanent removal of genes from the human
parasite Plasmodium falciparum requires the targeted integration of
plasmids into the genome by double cross-over homologous
recombination. This approach uses a ‘positive-negative’ selection
strategy and results in the introduction of drug resistance-markers
into the genome[6]. Specifically, transgenic parasites that have the
targeting construct integrated by single-cross over recombination
are first selected using one of a limited set of resistance markers
and drug combinations[5,6,7,8]. Subsequently, these parasites are
subjected to ‘negative’ drug selection to select for mutants that
have permanently removed the gene of interest by an internal
double cross-over recombination event[6,9]. The limited number
of resistance markers in P. falciparum severely compromises the
possibilities for sequential genetic modifications. As a result no P.
falciparum mutants have currently been reported where two or
more genes have been targeted by sequential transfection
procedureshttp:///. Therefore, there is a need for methodologies
that allow for the generation of mutants which lack resistance
markers and permit successive gene deletions within the same
genome.
A recent development using reverse genetics in rodent parasites
has been the generation and analysis of ‘attenuated’ parasites
engineered through gene-deletion. These genetically attenuated
parasites (GAP) can either become developmentally arrested
subsequent to invasion of liver cells [10] or infections with those
GAPs that are associated with a marked decrease in the virulence
in the host[11,12,13]. A number of these lines are now being tested
and used in research aimed at developing malaria vaccines that
consist of attenuated parasites. The translation of such genetically
modified parasites into human vaccines may require the removal
of resistance markers from the parasites genome. Specifically,
multiple gene deletions may be necessary to reach complete
attenuation and removal of resistance markers is essential in light
of regulations governing the use of genetically attenuated
organisms in vaccines[14,15]. Here we report on the development
of an efficient FLP recombinase system that in combination with
the positive-negative drug selection strategy permits the generation
of P. falciparum gene deletion mutants lacking resistance markers.
The yeast FLP recombinase recognizes a 34 nucleotide FLP
recognition target (FRT) site and excises any intermediate DNA
sequences located between two identically oriented FRT sites
(referred to FRTed sequence)[16]. The FLP/FRT system has been
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previously applied in Plasmodium for generation of a ‘conditional
knock-out’ system for deleting genes from the rodent parasite P.
berghei in mosquito stages[17,18,19]. However, using the FLP/
FRT system to efficiently delete genes in blood stage parasites has
not been reported. In this paper we now describe the removal of
the resistance marker using a 37uC thermostable enhanced FLP
recombinase from a parasite in which the neighbouring genes p52
and p36 were deleted. This mutant is actively being pursued as a
potential GAP for use in humans, using the standard approach of
generation gene deletion mutants[20,21]. The ability to remove
resistance markers from the P. falciparum mutant genome will be
important not only for research into parasite gene function but
also for generating genetically-modified parasites that may serve as
live, attenuated malaria vaccines.
Results
Generation of a gene deletion ‘FRT’ targeting construct
for P. falciparum
In order to permit removal of resistance markers from the
genome of P. falciparum during blood-stage culture, we introduced
2 FRT sites into the standard positive-negative transfection
construct (pHHT-FCU)[9] along with gene integration sequences
designed to simultaneously target the P. falciparum paralogous
genes, p52 and p36, resulting in the construct, pHHT-FRT-Pf5236
(Figure 1A). The genes p52 and p36 are a closely related and
paralogous pair of genes which are located in tandem on
chromosome 4 in the P. falciparum genome, separated by only
1.4 kb[20,21,22,23,24]. In the pHHT-FRT-Pf5236 construct the
FRT sites have been positioned to flank the two p52/p36 gene-
targeting regions in an identical orientation (Figure 1A). This
orientation should enable FLP-mediated excision of the hdhfr-
resistance cassette located between the FRT sites. We further
modified this vector by replacing the hdhfr resistance marker for a
hdhfr::gfp fusion gene, thereby producing the construct pHHT-
FRT-(GFP)-Pf5236 (Figure 1A). The hdhfr::gfp fusion gene permits
both the selection of transformed parasites by WR99210 treatment
and the visualization of transformed parasites by fluorescent
microscopy.
Generation and characterization of FRT containing
Dp5236 and Dp5236gfp parasites
The constructs pHHT-FRT-Pf5236 and pHHT-FRT-(GFP)-
Pf5236 were independently transfected into P. falciparum blood
stages using electroporation [25]. In these experiments double-
cross over gene deletion mutants were selected (referred to as
Dp5236 and Dp5236gfp) by standard positive -negative selection
using the drugs WR99210 and 5-FC respectively [9]. The correct
integration of the two constructs into the genome of parasites that
had undergone positive and negative drug selection was analysed
using an adapted long-range PCR (LR-PCR) method and
Southern Analysis. The ability to amplify .5 kb DNA sequences
by LR-PCR permits us to now rapidly screen the genotypes in
parental populations of transfected P. falciparum parasites (see
Material and Methods for details of the optimized LR-PCR
method). Using both LR-PCR and Southern analysis we
confirmed that deletion of p52/p36 by double cross-over
integration of the targeting constructs had occurred (Figure 1B,
C). Next, Dp5236gfp parasites were analyzed by fluorescence
microscopy and all parasites displayed GFP-expression (Figure 1D,
top panels).
Unlike in conventional P. falciparum gene deletion transfection
experiments parasite cloning was not performed at this stage and
we proceeded directly with the next step, specifically the removal
of the resistance marker between the 2 FRT sites from the genome
of Dp5236 and Dp5236gfp parasites. For excision of the FRTed
sequence, we generated two additional plasmids for transient
expression of FLP after episomal transfection into the FRT-
containing parasites.
Generation of FLP recombinase containing plasmids and
removal of resistance genes from Dp5236 and Dp5236gfp
parasites
Two plasmids were generated that contain an FLP recombinase
under the control of the hsp86 promoter and the blasticidin-S-
deaminase (bsd) resistance marker (see Material and Methods and
Figure S1A). The first construct, we term pMV-FLP, was
constructed by inserting the standard FLP encoding gene under
control of the constitutive P. falciparum hsp86 promoter (HSP86-
FLP-PBDT) into the pBSII-KS+ plasmid along with the positive
selection marker bsd-cassette under control of the P. falciparum hrp3
promoter (59HRPIII-BSD-39HRPII) derived from pCMB-
BSD[7]. The second construct, pMV-FLPe, was essentially
identical to pMV-FLP except that the standard FLP encoding
gene was replaced by a gene encoding FLPe. This plasmid was
termed pMV-FLPe. Whereas FLP, being derived from yeast, has
an enzymatic optimal temperature around 30uC[26], FLPe is a
37uC thermostable enhanced allozyme of FLP recombinase[27].
The Dp5236 and Dp5236gfp mutant parasites were transfected
with either the FLP or the FLPe containing plasmid and
transformed parasites were selected by blasticidin treatment[7].
The transformed parasites became apparent in the cultures
between day 6–13 after transfection. Interestingly, after transfec-
tion with these constructs we observed that both these enzymes,
FLP and FLPe, had an effect on growth of asexual blood stage
parasite (for more details please see Figure S1B and legends).
When we analysed the genotype of FLP-transfected parasites
after blasticidin selection we found evidence that in a small
percentage of parasites DNA sequences, including the resistance
genes, between the FRT sites (i.e. ‘FRTed’ sequence) had been
removed. LR-PCR of Dp5236gfp parasites, after FLP plasmid
transfection, amplified two fragments of 5.2 kb and 2.3 kb,
consistent with the retention of the selection marker and FRT-
mediated recombination, respectively (Figure 1B). The 2.3 kb
fragment was cloned and sequenced which confirmed the correct
excision of the FRTed sequence (data not shown). However, the
2.3 kb PCR fragment was very faint whereas the 5.2 kb fragment
of the region containing the FRTed sequence was rapidly
amplified (Figure 1C), indicating that most parasites still contained
the FRTed sequence. This was confirmed by fluorescence
microscopy as more than 99% of the FLP-transfected parasites
were GFP-positive. As the optimal temperature for FLP is
30uC[28], we also cultured the FLP-transfected parasites at
30uC for intermittent periods (4–48 hours). However, at 30uC
no increase in removal of the FRTed sequences was detected as
demonstrated by a similar high proportion (.99%) of GFP-
expressing parasites (data not shown).
In contrast to the FLP-transfected parasites, no GFP-positive
parasites were visible in the parasite populations after transfection
with the FLPe-containing plasmids (Figure 1D), indicating the
efficient removal of the FRTed resistance marker cassette. Further,
LR-PCR revealed only the 2.3 kb band, consistent with full
removal of the FRTed sequence and we were unable to detect the
5.2 kb fragment of parasites that retained the FRTed sequence.
These results indicate that FLPe mediated recombination between
the FRT sites is highly efficient resulting in removal of the FRTed
sequences in nearly 100% of the parasites. FLPe-transfected
parasites were cloned by the method of limiting dilution and
Resistant-Marker Free P. falciparum Mutants
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Southern analysis of cloned parasites confirmed correct excision
between the FRT sequences, resulting in excision of drug
selectable marker and gfp fusion cassette (Figure 1C). These results
demonstrate that the FLPe-recombinase system permits the
efficient generation of gene deletion mutants lacking resistance
markers.
Analysis of drug sensitivity and gametocyte production in
mutants after FLP-mediated removal of resistance genes
We next analyzed if the transfected parasites had retained their
capacity to produce gametocytes. The loss of gametocyte
production has been reported to frequently occur during
prolonged periods of in vitro cultivation and manipulation of P.
falciparum asexual blood stages[29]. A stable gametocyte produc-
tion is of particular importance for Dp5236 parasites, which are
being developed as potential attenuated sporozoite vaccines. For
both Dp5236*FLPe and Dp5236gfp*FLPe, gametocyte production,
as determined by counting stage II and stage IV-V gametocytes, as
well as male gamete formation as determined by counting
exflagellation centres was comparable to wild-type (NF54)
parasites (Table 1).
In order to create multiple gene deletions within the same
parasite, it is critical that after the action of FLPe mutant parasites
Figure 1. FLPe mediated excision of resistance markers from P.falciparum gene deletion mutants. (A) Schematic representation of the
genomic locus of wild-type (WT), gene deletion mutant Dp5236gfp before and after removal of the hdhfr::gfp resistance marker. The construct (pHHT-
FRT-(GFP)-Pf5236) for targeting deletion of the p52 and p36 genes contains the two FRT sequences (red triangles) that are recognized by FLP. P1, P2:
primer pairs for LR-PCR analysis; B (BclI),H (HindIII), E(EcoRI): restriction sites used for Southern analysis; cam: calmodulin; hrp: histidine rich protein;
hsp: heatshock protein; fcu: cytosine deaminase/uracil phosphoribosyl-transferase; pbdt: P.berghei dhfr terminator. (B) Long range PCR analysis of
genomic DNA from WT and mutants Dp5236 and Dp5236gfp before and after transfection with constructs containing FLP or FLPe, confirming removal
of the hdhfr::gfp resistance marker in FLPe-transfected parasites. See A for location of the primers p1 and p2 and the expected product sizes (i.e. WT,
4.8 kb; Dp5236, 4.6 kb; Dp5236gfp, 5.2 kb; Dp5236gfp*FLPe and Dp5236*FLPe, 2.3 kb). (C) Southern analysis of restricted genomic DNA from WT and
mutants before and after transfection with constructs containing FLPe, confirming removal of the hdhfr::gfp resistance marker in the FLPe-transfected
Dp5236gfp mutant. Upper panel: DNA was digested with HindIII/EcoRI (probed with p52 targeting sequence); Lower panel DNA digested with BclI
(probed with p36 targeting sequence). (D) Analysis of GFP expression in mutant Dp5236gfp before and after transfection with constructs containing
FLPe, confirming removal of the hdhfr::gfp resistance marker in the FLPe-transfected parasites.
doi:10.1371/journal.pone.0015121.g001
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must regain sensitivity to the drugs used during selection. This can
only be achieved if the hdhfr selection marker is completely absent
from the parasite genome and that the FLPe/bsd containing
plasmid is lost from the parasites after release of the drug pressure.
The loss of these plasmids is thought to happen rapidly in parasites
after the release of blasticidin pressure due to uneven segregation
of such DNA elements into daughter merozoites. However, it has
been reported that parasites can spontaneously acquire blasticidin
resistance when exposed to sustained blasticidin treatment
independent of the bsd-selectable marker [30]. We therefore tested
the sensitivity of blood stages to both blasticidin and WR99210
using standard drug-susceptibility assays. We demonstrate that
parasites have not acquired blasticidin resistance (Figure 2A). In
addition the Dp5236gfp*FLPe parasites had regained the sensitivity
to WR99210 after the recombinase treatment (Figure 2B).
Generation of a generic gene-deletion construct
containing FRT sites
We have generated a ‘standardised’ FRT gene-deletion
construct, which contains FRT sites next to the gene targeting
regions. These gene targeting regions can easily be exchanged for
any gene of interest (see Figure S1C). This generic construct is an
adapted version of the standard construct pHHT-FCU (see
Material and Methods for construct details) that has two P52
target regions introduced into SacII/HpaI digested pHHT-FCU (59
-target region) and into NcoI/EcoRI digested pHHT-FCU (39-
target region). The two FRT sites reside just next to the targeting
regions and flank the selectable marker. Each target region
contains 4 unique restriction sites; for the 59target region BsiWI/
MluI, BssHII/SacII and for the 39target region NcoI/NheI, KpnI/
XmaI (Figure S1C).
Discussion
In the absence of efficient forward genetic screens in malaria
research, the targeted deletion/mutation of Plasmodium genes is
now one of the most important methodologies to study the
function of malaria parasite genes. However, the low efficiency of
targeted gene deletion, the slow process of selecting gene deletion
mutants and the limited number of drug-resistance markers greatly
limits the analysis of Plasmodium genes. This analysis is of particular
importance as more than 50% of Plasmodium genes have no
homologs in other species (annotated ‘unknown function’) and the
proteins encoded by a number of these genes maybe attractive
targets for drugs or vaccines. To date there are no reported P.
falciparum mutants that have had multiple, non-neighbouring,
genes deleted. Here we describe a method of generating gene
deletions in P. falciparum that makes use of the yeast FLP-
recombinase enzyme to remove introduced resistance-markers and
other plasmid DNA sequences from the mutants. This method-
ology facilitates the generation of multiple gene deletions or gene
mutations in P. falciparum which is important in uncovering
Plasmodium specific functions and processes. Moreover, this
technique facilitates the generation of genetically attenuated
parasites (GAP) permitting the removal of multiple genes. Gene
deletion mutants of human malaria parasites, which completely
Table 1. Gametocyte production and male gamete formation (exflagellation) of wild type (WT) and mutants, Dp5236 and
Dp5236gfp, before and after FLPe action.
Parasite line No of gametocytes stage II (range)1 No of gametocytes stage IV-V (range) 1 Exflagellation2
WT 10 (2–24) 50 (39–58) ++
DP5236 11(4–17) 52(44–59) ++
DP5236GFP 11(8–15) 49(8–65) ++
DP5236*FLPe 11(6–15) 67(54–79) ++
DP5236GFP*FLPe 9(2–23) 62 (50–72) ++
1Number of gametocytes per 1000 erythrocytes counted in Giemsa stained thin blood smears.
2Exflagellation centers counted in wet mounted preparations of stimulated gametocyte cultures at 400x magnification using a light microscope; ++ score =.10
exflagellation centers per microscope field.
doi:10.1371/journal.pone.0015121.t001
Figure 2. Drug sensitivity of wild type (WT) and Dp5236gfp
parasites. Drug sensitivity to (A) blasticidin and (B) WR99210 of blood
stages of WT and mutant Dp5236gfp parasites before and after
transfection with constructs containing FLPe.
doi:10.1371/journal.pone.0015121.g002
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arrest during their development inside hepatocytes, are currently
being intensely investigated as potential whole-organism malaria
vaccines[10,20,21].
An advantage of the high efficiency of removal of FRTed
sequences (.99%) from the mutant parasite genome by FLPe is
that it is not necessary to clone the parasites before transfection
with the FLPe-plasmid, thereby reducing the time for generation
of the desired mutants. Consequently, the whole procedure of
generating a gene-deletion mutant without resistance marker takes
18 weeks as compared to 15 weeks it currently takes to generate
(double cross-over) gene deletion mutants with a selectable marker.
In Figure 3 we show a schematic representation detailing and
comparing the standard gene deletion with the FRT/FLPe
deletion-recycling method described in this paper (Figure 3).
The use of the FLP/FRT system for gene removal in Plasmodium
has been previously reported for the rodent parasite, P. berghei.
However, this strategy permits deletion of genes only during
development of the parasite in the mosquito. The method also
consists of inserting FRT sites around the locus of interest in a
parasite that expresses FLP recombinase driven from a mosquito
stage-specific promoter[17,18,19]. The system makes use of either
FLP or a low-activity FLP enzyme, termed FLPL. The activity of
FLPL is greatly reduced at 37uC and maintained at this reduced
level at 20uC–25uC, temperatures permissive for parasite develop-
ment in the mosquito. Because this strategy to delete genes requires
passage of the parasites through mosquitoes it will be extremely
difficult to adapt this methodology to P. falciparum. Attempts to adapt
the FLP or FLPL based system to delete genes during blood stage
development have so far been unsuccessful. Analysis in blood stage
of P. berghei only very low recombination efficiencies have been
observed after prolonged cultivation in either FLP- or FLPL-
expressing parasites at temperatures ranging from 21–37uC
(personal observations; M.R. van Dijk and A.P. Waters personal
communication). This low level of excision in P. berghei blood stages
mediated by FLP or FLPL was comparable to that what we have
observed with FLP-based excision of FRTed sequences in P.
falciparum blood stages. The strong increase in recombination
(.99%) observed with FLPe indicates that the use of the 37uC
variant of FLP (i.e. FLPe) is the most important adaptation
permitting efficient excision of heterologous DNA sequences.
Interestingly we found that both FLP and FLPe had an ‘off target’
effect on blood stage development in culture, resulting in a reduced
growth rate and/or arrest in parasite development. However, a
beneficial side-effect of the growth delay of parasites containing
FLPe-episomes is that those parasites that lose the FLP-plasmid
after removal of BSD selection will outgrow the parasites that still
retain FLPe-episomes. This then results in the enhancement of
selection of episome-free parasites with the resistance marker
removed. Indeed, we were unable to detect the FLPe construct by
PCR at 3 weeks after the removal of BSD selection (data not shown).
We are now using the Dp5236 parasites generated in this study
as the basis for introducing additional marker-free gene deletions
in order to generate a GAP-vaccine that is not only potent but also
safe for human use, specifically GAPs that are compromised at
multiple points of development (multiple-deletions) and without
the addition of heterologous sequences (i.e. no resistance markers).
The procedures of efficient removal of drug-resistance markers in
gene deletion mutants that do not affect either gametocyte
production or drug-sensitivity, demonstrate that the FLPe
recombinase system is an effective and powerful tool that offers
new opportunities for P. falciparum transgenesis, both for the
analysis of gene function and for the generation of genetically
attenuated parasites - making the removal of resistance genes and
multiple gene-deletion mutants possible.
Figure 3. Schematic representation of the generation of FLPe-
mediated ‘resistance marker-free’ P. falciparum mutants. Stan-
dard gene deletion by double cross-over (DXO) homologous recombi-
nation (left hand side) is compared to gene deletion using the FLPe-
recombinase method described in this paper (right hand side). Both
methods are essentially identical up to 10 weeks. First transformed
parasites are treated by on/off cycling with the antimalarial drug
WR99210 (POS SELECTION) to select for mutant parasites where the
plasmid has become integrated into the genome by single cross-over
(SXO) homologous recombination. Next negative drug selection (NEG
SELECTION) using the drug 5-FC is applied to select for those parasites
where an internal recombination (DXO) between plasmid and genomic
sequences has occurred and the target gene is deleted. At this stage all
transformed parasites are GFP positive as the hdhfr-resistance marker is
fused to GFP. At this point conventional DXO gene deletion parasites are
cloned by a method of limiting dilution. At week 15 cloned parasites still
containing the resistance marker (+SM; shown in the standard DXO
genotype schematic as a green arrow) can be expanded. In the FLPe
recombinase method the gene deletion mutants selected after positive/
negative selection are not cloned but immediately transformed with a
plasmid encoding the enhanced FLP recombinase (pMV-FLPe). This
plasmid is maintained episomally through blasticidin selection (BSD
SELECTION) for one week after which BSD selection is released and once
these parasites are detected in culture they are cloned by limiting dilution.
At week 18, only 3 weeks longer than standard method, these resistance
marker–free parasites can be expanded. Removal of the resistance marker
is confirmed by the absence of GFP-expression as recombination between
the introduced FRT sites (red triangles) has occurred removing plasmid,
gfp and drug resistance marker sequences (-SM).
doi:10.1371/journal.pone.0015121.g003
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While this manuscript was under review, a very similar method
to re-cycle drug selectable markers in P. falciparum was published.
In this study O’Neill and colleagues demonstrated that highly
efficient site-specific recombination, removing introduced DNA,
was obtained using Cre recombinase and loxP sites[31].
Interestingly, they observed very low levels of recombination, as
did we, with standard (30uC optimal) FLP recombinase but do not
report testing a 37uC optimised variant of FLP.
Material and Methods
Culture of P. falciparum blood stages and parasite
cloning
Blood stages of P. falciparum parasites of line NF54 (wild-type;
WT) and the different mutants generated in this study (see below)
were cultured using in vitro culture conditions for P. falciparum
previously described[32,33,34]. Subcultures of the different lines
were established in the same semi-automated culture system. Fresh
human red blood cells were obtained from Dutch National blood
bank (Sanquin Nijmegen, NL; permission granted from donors for
the use of blood products for malaria research), washed in serum
free medium, and these were added to these cultures at
parasitemias between 2–7%, thereby reducing the parasiteamia
to 0.5% while maintaining a 5% hematocrit. Induction of
gametocyte production in these cultures was performed as
previously described[32,33,34].
Cloning of transgenic parasites was performed by the method of
limiting dilution in 96 well plates[35]. Parasites of the positive wells
were transferred to the semi-automated culture system and
cultured for further phenotype and genotype analyses (see below).
Generation of DNA constructs
The pf52 and pf36 genes (PFD0215c and PFD0210c) of P.
falciparum were disrupted using an adapted version of the standard
construct (pHHT-FCU) for gene deletion using positive/negative
selection procedure[9]. The pHHT-FRT-Pf5236 targeting con-
struct was generated by inserting target sequences including FRT
sites (in italic) for p52 (primers BVS25: CATGCAATTG-
aagttcctattctctagaaagtataggaacttcaattcacaagcaactaaaatcaatatcc; 1638:
CATGCCATGGtttgaataagttttacaacctgc) digested with MfeI and
NcoI and p36 (primers BVS18: GAATTCGATATCgaagttcctatactttc-
tagagaataggaacttccactcgaatgtgggatggcatcc; 2589 (tccccgcggATGAG-
GTACATTCTCAGGAATC) digested with EcoRV and SacII into
the EcoRI, NcoI and HpaI, SacII sites respectively of pHHT-FCU.
For construction of pHHT-FRT-(GFP)-Pf5236 the hdfr resistance
gene was replaced by cloning the HindIII and SacI digested hdfr-gfp
fusion gene fragment from plasmid pBKHGint (Christian Flueck,
unpublished) into HindIII and SacI digested pHHT-FRT-Pf5236.
Two plasmids were generated that contain an FLP recombinase
under the control of the hsp86 promoter and the blasticidin-S-
deaminase (bsd) resistance marker. The first construct, pMV-FLP
was constructed by inserting the standard FLP gene as a 1322 bp
fragment PCR amplified from plasmid FLP@UIS4 (kindly
provided by Robert Menard, Pasteur Institute, Paris, France)
using primers BVS53 (59-GGTCCTCGAGatggtttccctttccc) and
BVS54 (59-TCGCCTCGAGttatatgcgtctatttatgtaggatg), into XhoI
digested pHHT-FCU replacing the fcu open reading frame and
subsequently cloning the NotI/SacII HSP86-FLP-pBDT fragment
into the NotI/SacII digested pBSII-KS+ plasmid (Stratagene). The
bsd-cassette (59HRPIII-BSD-39HRPII) derived from pCMB-
BSD[7] was introduced in this plasmid through KpnI/PstI cloning
of the 2800 bp 59HRPIII-BSD-39HRPII fragment, resulting in
plasmid pMV-FLP. The second construct, pMV-FLPe, was
constructed by inserting the standard FLPe (a 37uC thermostable
enhanced allozyme of FLP recombinase[27]) gene as a 1340 bp
fragment PCR amplified from plasmid pGaggs-FLPe (obtained via
Addgene; www.addgene.org) using primers BVS120 (59- gggtcga-
cAGATCTCACCATGGCTCCCAAGAAGAAGAGG) and
BVS121 (59- gggtcgacCTCGACTCTAGATCATTATATGCG)
into the XhoI digested pMV-FLP plasmid, resulting in plasmid
pMV-FLPe.
A generic construct containing FRT sites was made in which
target regions are easily exchanged to target any gene of interest.
The construct is an adapted version of the standard construct
(pHHT-FCU; see above for construct details) in which P52 target
regions including FRT sites were introduced (59p52with primer bvs29
(59agcatgCCGCGGCGCGCTGCCAGAATGTTCTTGTTCG)
and bvs30 (59 CATGGTTAACGAAGTTCCTATACTTTCTAG-
AGAATAGGAACTTCGTACGCGTgcctttgttaatcaaagtaatccaaccg)
into SacII/HpaI digested pHHT-FCU and for 39p52 primer
bvs31(59 agcatgGAATTCGAAGTTCCTATTCTCTAGAAAGT-
ATAGGAACTTCccgggtaccCATATATTATATGTTCCTCTTG)
and bvs32(59 AGCATGCCATGGCTAGCcatacactttttctcatgag) into
NcoI/EcoRI digested pHHT-FCU). Each target region contains
4 unique restriction sites for the 59target region BsiWI/MluI,
BssHII/SacII and for the 39target region NcoI/NheI, KpnI/XmaI
(SOM Fig. 1C). A P52-FRT containing generic construct and
pMV-FLPe are available on request for research purposes.
DNA fragments were amplified by PCR amplification (Phusion,
Finnzymes) from genomic P. falciparum DNA (NF54 strain) or from
the described plasmids and all PCR fragments were sequenced
after TOPO TA (Invitrogen) sub-cloning.
Transfection and selection of transgenic parasites
Transfection of blood-stage parasites was performed as
described[25] using a BTX electroporation system. Transfected
parasites were cultured in a semi automated culture system.
Selection of gene deletion mutants by positive and negative
selection procedures were performed as described[9]. Transfection
of gene deletion mutants with constructs containing FLP or FLPe
(plasmids pMV-FLP, pMV-FLPe) and selection of blasticidin
resistant parasite populations was performed as described[7].
Genotype analysis of transgenic parasites
Genotype analysis of transformed parasites was performed by
Expand Long range dNTPack (Roche) diagnostic PCR (LR-PCR)
and Southern blot analysis. Genomic DNA of blood stages of WT
or mutant parasites was isolated as described[36] and analyzed by
LR-PCR using primer pair (p1, p2) 3258 (59-TAAACCTATTT-
GAAGCTTTATAC) and 3259 (59-CTTGTGGGAAATTA-
CAATGAC) for correct integration of construct p5236FRT in
the pf52/36 locus by double cross over integration. The LR-PCR
program has an elongation step of 62uC[26] for 10 minutes, and
an annealing step of 48uC for 30 seconds. All other PCR settings
were according to manufacturers instructions.
For Southern blot analysis, genomic DNA was digested with
EcoRI/HindIII or with BclI for analysis of disruption of pf52 and
pf36 respectively. DNA was size fractionated respectively on a
0.7% or 1% agarose gel and transferred to a Hybond-N
membrane (Amersham) by gravitational flow[36]. The blot was
pre-hybridized in Church buffer[37] followed by hybridization to
a pf52 and pf36 specific probes (pHHT-FRT-Pf5236 or pHHT-
FRT-(GFP)-Pf5236 digested with NcoI/XbaI (1089 bp) or SacII/
XbaI (902 bp) respectively) constituting the sequences used as
target sequences for integration (see above). Both probes were
labelled using the High Prime DNA labelling kit (Roche) and
purified with Micro Biospin columns (Biorad).
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Fluorescence microscopy
Samples (2 ml) of infected red blood cells from cultures with
parasitemias between 2 and 10% were incubated with Hoechst
33258 (10 mM) for 20 minutes at 37uC before mounting on a
sealed cover slip slide. Hoechst- and GFP-fluorescence were
analysed using a Zeiss Fluorescence microscope (1000x magnifi-
cation) and Axiovision software.
Gametocyte and male gamete production
Gametocyte production was established in cultures at day 13-15
after start of the gametocyte cultures by counting the number of
mature gametocytes (stage II and stages IV/V) in Giemsa stained
thin blood films[32]. Male gamete formation was determined by
activation of exflagellation. Samples of 10 ml were taken from the
cultures, infected red blood cells pelleted by centrifugation and
resuspended in 10 ml of Foetal Calf Serum (pH 8.0) at room
temperature for 10 minutes and then mounted on a cover slip.
Exflagellation centers were counted under the light-microscope in
5 homogeneous fields of a single cell layer of red blood cells at a
400x magnification. The samples were scored as follows: if the
mean number of exflagellation centers was .10/field they were
scored as ++; ,10/field they were scored as +; and none was
scored as 0.
Drug sensitivity assays
Drug sensitivity was analyzed as described[38] with some
modifications. Briefly, infected blood cells (1% parasitemia) were
cultured using the Candle Jar method in 24 wells culture plates
containing serial drug dilutions of either WR99210[25] (Jacobus
Pharmaceutical Company) or blasticidin[7] (Invitrogen). Medium
was changed daily. The parasitemia in all culture wells was
determined 96 hours after the start of the cultures by counting
infected erythrocytes in Giemsa stained thin blood smears. The
non-linear regression function for sigmoidal dose-response (vari-
able slope) of the GraphPad Prism software is used to calculate the
(best-fit) inhibitory concentration (IC50) values.
Supporting Information
Figure S1 (A) FLP/FLPe recombinase containing con-
struct. The construct for transient expression of standard FLP
recombinase (plasmid pMV-FLP) or its 37uC thermostable
enhanced allozyme, FLPe (plasmid pMV-FLPe). The flp and flpe
genes are under the control of the hsp80 promoter. These plasmids
contain the blasticidin-s-deaminase (bsd) gene under control of the
hsp86 promotor. hrp: histidine rich protein; pbdt: P.berghei dhfr
terminator. (B) Delayed growth phenotypes of FLPe
expressing blood stages in subcultures. Growth of blood
stages of wild type and mutant parasites in the presence or absence
of FLPe expression in subcultures, showing a delayed growth
phenotype in the presence FLPe expression. Solid arrows: Dilution
of Dp5236gfp subculturing to 0.5% parasiteamia with fresh
erythrocytes. Dashed arrow: Dilution of WT*FLPe subculture
with fresh erythrocytes. (C) Generic pHHT-FRT-(GFP)-Pf52
construct. The construct (pHHT-FRT-(GFP)-Pf52) for targeting
deletion of the p52 gene contains the two FRT sequences (red
triangles) that are recognized by FLP. Indicated are the restriction
sites that are introduced to facilitate exchange of p52 targeting
regions with targeting regions of other genes of interest. Each
target region contains 4 unique restriction sites for the 59target
region BsiWI/MluI, BssHII/SacII and for the 39target region NcoI/
NheI, KpnI/XmaI. cam: calmodulin; hrp: histidine rich protein; hsp:
heatshock protein; fcu: cytosine deaminase/uracil phosphoribosyl-
transferase; pbdt: P.berghei dhfr terminator.
(TIF)
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